Katia Scotlandi Selected Research

Ewing Sarcoma (Sarcoma, Ewing)

4/2022	Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma.
3/2022	miR-214-3p Is Commonly Downregulated by EWS-FLI1 and by CD99 and Its Restoration Limits Ewing Sarcoma Aggressiveness.
1/2022	Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma.
1/2022	Novel Targeting of DNA Methyltransferase Activity Inhibits Ewing Sarcoma Cell Proliferation and Enhances Tumor Cell Sensitivity to DNA Damaging Drugs by Activating the DNA Damage Response.
1/2022	Targeting CD99 Compromises the Oncogenic Effects of the Chimera EWS-FLI1 by Inducing Reexpression of Zyxin and Inhibition of GLI1 Activity.
9/2020	Circulating miR34a levels as a potential biomarker in the follow-up of Ewing sarcoma.
1/2020	Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Modulates Aggressiveness of Ewing Sarcoma by Regulating the CD164-CXCR4 Axis.
1/2019	Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations.
3/2018	CD99 at the crossroads of physiology and pathology.
1/2018	Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Katia Scotlandi Research Topics

Disease

77	Neoplasms (Cancer) 04/2022 - 02/2002
45	Ewing Sarcoma (Sarcoma, Ewing) 04/2022 - 03/2002
37	Osteosarcoma (Osteogenic Sarcoma) 02/2022 - 01/2002
22	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 12/2002
18	Neoplasm Metastasis (Metastasis) 01/2022 - 03/2002
6	Rhabdomyosarcoma 04/2022 - 03/2002
5	Prostatic Neoplasms (Prostate Cancer) 01/2017 - 07/2014
4	Disease Progression 09/2020 - 05/2011
3	Carcinogenesis 01/2021 - 09/2002
3	Chondrosarcoma 01/2020 - 06/2013
2	Inflammation (Inflammations) 12/2021 - 09/2012
2	Synovial Sarcoma (Synovioma) 01/2021 - 08/2014
2	Hypoxia (Hypoxemia) 01/2013 - 10/2011
1	Giant Cell Tumors (Giant Cell Tumor) 06/2022
1	Necrosis 01/2022
1	Rheumatoid Arthritis 12/2021
1	Osteoarthritis 12/2021
1	Pathologic Processes 01/2020
1	Cardiomyopathies (Cardiomyopathy) 01/2019
1	Friedreich Ataxia (Friedreich's Ataxia) 01/2019
1	Heart Diseases (Heart Disease) 01/2019
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2019
1	Iron Overload 01/2019
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2019
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2019
1	Progeria (Hutchinson Gilford Syndrome) 10/2018

Drug/Important Bio-Agent (IBA)

15	Proteins (Proteins, Gene)FDA Link 12/2021 - 03/2002
13	Pharmaceutical PreparationsIBA 01/2021 - 12/2002
11	Insulin-Like PeptidesIBA 01/2021 - 09/2006
10	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 09/2005
9	Biological ProductsIBA 12/2021 - 03/2002
8	MicroRNAs (MicroRNA)IBA 02/2022 - 03/2012
7	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 02/2002
7	IGF Type 1 Receptor (IGF 1 Receptor)IBA 09/2012 - 03/2002
6	RNA (Ribonucleic Acid)IBA 01/2022 - 07/2014
6	ParaffinIBA 06/2016 - 09/2004
5	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2022 - 01/2002
5	Cisplatin (Platino)FDA LinkGeneric 01/2018 - 12/2002
5	Methotrexate (Mexate)FDA LinkGeneric 04/2009 - 12/2002
4	Lamin Type A (Lamin A)IBA 04/2022 - 12/2008
4	TrabectedinIBA 01/2022 - 12/2002
4	Biomarkers (Surrogate Marker)IBA 09/2020 - 07/2014
4	Carrier Proteins (Binding Protein)IBA 01/2020 - 01/2010
4	Messenger RNA (mRNA)IBA 01/2020 - 01/2010
4	Antineoplastic Agents (Antineoplastics)IBA 01/2019 - 12/2002
4	AntibodiesIBA 01/2013 - 09/2007
4	Vincristine (Oncovin)FDA LinkGeneric 01/2013 - 05/2005
3	EWS-FLI fusion proteinIBA 03/2022 - 11/2014
3	MethyltransferasesIBA 01/2022 - 01/2018
3	dactolisibIBA 01/2022 - 01/2010
3	Caveolin 1IBA 01/2019 - 04/2006
3	CaspasesIBA 03/2018 - 07/2004
3	Insulin ReceptorIBA 01/2015 - 09/2012
3	Insulin (Novolin)FDA Link 02/2014 - 01/2013
3	Somatomedin Receptors (Somatomedin Receptor)IBA 01/2013 - 01/2004
3	NVP-AEW541IBA 09/2012 - 05/2005
3	Insulin-Like Growth Factor I (IGF-1)IBA 09/2012 - 01/2004
3	Complementary DNA (cDNA)IBA 01/2008 - 04/2003
2	Decitabine FDA Link 02/2022 - 01/2019
2	MC3343IBA 01/2022 - 01/2018
2	Transcription Factors (Transcription Factor)IBA 01/2022 - 03/2011
2	Ifosfamide FDA LinkGeneric 01/2022 - 05/2005
2	ZyxinIBA 01/2022 - 07/2004
2	quinolineIBA 01/2019 - 01/2018
2	EnzymesIBA 01/2019 - 01/2011
2	Membrane Proteins (Integral Membrane Proteins)IBA 03/2018 - 01/2018
2	Monoclonal AntibodiesIBA 03/2018 - 08/2014
2	Oncogene Proteins (Oncogene Protein)IBA 02/2016 - 07/2008
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2015 - 06/2003
2	Metformin (Glucophage)FDA LinkGeneric 01/2013 - 01/2013
2	Glutathione Transferase (Glutathione S-Transferase)IBA 01/2011 - 08/2008
2	Phosphotransferases (Kinase)IBA 08/2007 - 05/2005
2	Alkaline PhosphataseIBA 04/2004 - 12/2002
1	Denosumab FDA Link 06/2022
1	idelalisibIBA 04/2022
1	hydrogen sulfite (bisulfite)IBA 02/2022
1	MTOR InhibitorsIBA 01/2022
1	mifamurtideIBA 01/2022
1	A-Form DNA (A-DNA)IBA 01/2021
1	Sunitinib (Sutent)FDA Link 01/2021
1	NivolumabIBA 01/2021
1	Eph Family Receptors (Eph Receptors)IBA 01/2021
1	CholesterolIBA 01/2020
1	Adenosine Triphosphate (ATP)IBA 01/2020
1	prelamin AIBA 01/2020
1	ATP-Binding Cassette Transporters (ABC Transporters)IBA 01/2020
1	ChemokinesIBA 01/2020
1	Azacitidine (5 Azacytidine)FDA Link 01/2019
1	IronIBA 01/2019
1	HepcidinsIBA 01/2019
1	metal transporting protein 1 (ferroportin)IBA 01/2019
1	Cadherins (E-Cadherin)IBA 01/2019

Therapy/Procedure

30	Therapeutics 01/2022 - 01/2006
12	Drug Therapy (Chemotherapy) 09/2020 - 12/2002
4	Neoadjuvant Therapy 10/2009 - 12/2006
2	Precision Medicine 01/2020 - 01/2013
2	Radiotherapy 01/2020 - 01/2006
2	Adjuvant Chemotherapy 09/2016 - 01/2006
2	Combined Modality Therapy 02/2016 - 01/2006
2	Aftercare (After-Treatment) 02/2007 - 12/2002